Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood

• Publication date

  2017-12-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V130.SUPPL_1.89.89
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies

  2024cites this paper
• Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

  2024cites this paper
• Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors

  2023cites this paper
• Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022

  2022cites this paper
• Non‐factor therapies for bleeding disorders: A primer for the general haematologist

  2022cites this paper
• An update of the current pharmacotherapeutic armamentarium for hemophilia A

  2021cites this paper
• Bispecific antibodies for the treatment of hemophilia A

  2021cites this paper
• Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors

  2021cites this paper
• Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery

  2021cites this paper
• Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis

  2021cites this paper
• Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature

  2021cites this paper
• Advances in the management of haemophilia: emerging treatments and their mechanisms

  2021cites this paper
• Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

  2021cites this paper
• Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel

  2020cites this paper
• Emicizumab for the treatment of acquired hemophilia A.

  2020cites this paper
• Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

  2020cites this paper
• Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring

  2020cites this paper
• Electrophysiological Procedures in Patients With Coagulation Disorders　- A Systemic Review.

  2020cites this paper
• Invasive procedures in patients with haemophilia: Review of low‐dose protocols and experience with extended half‐life FVIII and FIX concentrates and non‐replacement therapies

  2020cites this paper
• Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

  2020cites this paper
• Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A

  2020cites this paper
• Emicizumab treatment and monitoring in a paediatric cohort: real‐world data

  2020cites this paper
• Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors

  2020cites this paper
• Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab.

  2020cites this paper
• What proceduralists need to know about emicizumab for patients with hemophilia A

  2020cites this paper
• Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors

  2020cites this paper
• Emicizumab and the Clinical Coagulation Laboratory

  2020cites this paper
• bleeding and subsequent treatment with on-demand coagulation factors, surgical

  2020cites this paper
• New therapies using nonfactor products for patients with hemophilia and inhibitors.

  2019cites this paper
• Current and emerging biologics for the treatment of hemophilia

  2019cites this paper
• Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors

  2019cites this paper
• Managing Preoperative Hemostasis in Patients with Inherited and Acquired Bleeding Disorders

  2019cites this paper
• Parathyroidectomy in a patient treated with emicizumab

  2019cites this paper
• Hemophilia in a Changing Treatment Landscape.

  2019cites this paper
• Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement

  2019cites this paper
• Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti‐idiotype monoclonal antibodies: reply

  2019cites this paper
• Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement

  2019cites this paper
• Emicizumab use in major orthopedic surgery.

  2019cites this paper
• Emicizumab for the prevention of bleeds in hemophilia A

  2019cites this paper
• Emicizumab for hemophilia A without inhibitors

  2019cites this paper
• Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention

  2019cites this paper
• Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays

  2019cites this paper
• Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations

  2019cites this paper
• Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors—a single‐center cohort

  2019cites this paper
• Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors: a systematic literature review.

  2019cites this paper
• Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti‐idiotype monoclonal antibodies

  2018cites this paper
• Novel therapeutics for hemophilia and other bleeding disorders.

  2018cites this paper
• Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

  2018cites this paper
• The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A

  2018cites this paper
• Emicizumab for hemophilia A with factor VIII inhibitors

  2018cites this paper
• Emicizumab: Review of the literature and critical appraisal

  2018cites this paper
• Corrected: Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab

  year unknowncites this paper